The European Medicines Agency (EMA) – the European Union’s health regulator – has accepted for review the Dupixent product being developed by drugmakers Sanofi and Regeneron.

An atopic dermatitis treatment in Phase III development by Regeneron Pharmaceuticals and Sanofi met primary endpoints in two placebo-controlled trials.

In mid-May, pharma giant Pfizer agreed to buy Anacor Pharmaceuticals for a total transaction value, net of cash, of $5.2 billion. Anacor is a biopharmaceutical company concentrated on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform.

BALLERUP, Denmark , Nov. 11, 2015 /CNW/ – LEO Pharma A/S, a global healthcare company dedicated to helping people achieve healthy skin, and Japanese pharmaceutical company Astellas Pharma Inc. today announced that they have entered into an Asset Purchase Agreement under which Astellas will transfer its global dermatology business to LEO Pharma for € 675 […]

Patients who try to save money by getting generic prescriptions for creams and ointments to treat skin conditions like eczema and psoriasis may face sticker shock at the pharmacy, a U.S. study suggests. Researchers compared the average co-payments, or out-of-pocket prices, for several commonly prescribed topical corticosteroids, which have been used for decades to treat […]